Interim report January-June 2009

Interim report January-June 2009 

• Group revenues from sales of goods and royalties amounted to 721 (630) MSEK. 

• Earnings per share amounted to 5.95 (0.32) SEK. 

• Operating income amounted to 625 (39) MSEK. 

• Revenues within the Esthetics product area amounted to 591 (516) MSEK and
operating income was 142 (118) MSEK.

• Net income after tax amounted to 592 (32) MSEK.

April - June
• Group revenues from sales of goods and royalties amounted to 382 (341) MSEK
during the second quarter and operating income amounted to 571 (29) MSEK.
Operating income for the Esthetics product area amounted to 92 (63) MSEK and 
498 (-8) MSEK for the Hospital Healthcare product area.

• Net income after tax amounted to 550 (22) MSEK during the second quarter.

• In April 2009 Q-Med AB and Oceana Therapeutics, LCC., based in the US, entered
into global agreements regarding commercialization rights to Deflux® and
Solesta™. As part of the transaction Oceana acquired Q-Med Scandinavia, Inc. In
June 2009 
Q-Med received 60 MUSD, corresponding to 502 MSEK and additional 15 MSEK for
Oceana's share of the clinical trial costs, which under the agreements the
parties will share. The net revenue from the divestment, that is after the
deduction of acquisition costs, together with payment for the clinical trial
costs, amounted to 496 MSEK and this has been reported under Other operating
revenues.

Important events after the end of the period
• Q-Med's Premarket Approval (PMA) application for Durolane™ will be discussed
on August 19 2009, at a public meeting of the FDA's Orthopaedic and
Rehabilitation Devices Advisory Committee. The panel is expected to consider the
clinical trial results Q-Med submitted to support the approval and labelling of
Durolane, a single dose product for the treatment of pain caused by
osteoarthritis of the knee.

Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: + 46 70 974 9025  
Alexander Kotsinas, Vice President and CFO
Tel: +46 73 500 1111

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta™ for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q- Med today
has approximately 650 coworkers, with close to 400 at the company's head office
and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of NASDAQ OMX Nordic.